LAVA Therapeutics Faces Nasdaq Delisting, Changes Leadership
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Risk Level | high |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $1.04 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, leadership-change, control-change
Related Tickers: LVTX
TL;DR
LAVA's Nasdaq listing is in jeopardy, leadership is changing, and a control shift is happening.
AI Summary
LAVA Therapeutics N.V. announced on November 12, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is also undergoing a change in control and has appointed new officers and directors. This filing details the departure of certain officers and the election of new directors, alongside compensatory arrangements for these officers.
Why It Matters
This filing signals significant operational and financial challenges for LAVA Therapeutics, potentially impacting its stock value and future funding prospects.
Risk Assessment
Risk Level: high — The company has received a delisting notice from Nasdaq, indicating a severe risk to its continued trading on a major exchange.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange where listing requirements are not met
- November 12, 2025 (date) — Date of earliest event reported
FAQ
What specific continued listing rule did LAVA Therapeutics fail to meet according to the Nasdaq notice?
The filing states that LAVA Therapeutics received a notice from the Nasdaq Stock Market indicating a failure to satisfy a continued listing rule or standard, but the specific rule is not detailed in this excerpt.
When was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 12, 2025.
What are the main categories of information being reported in this 8-K filing?
The main categories reported are Notice of Delisting or Failure to Satisfy a Continued Listing Rule, Changes in Control of Registrant, Departure/Election of Directors and Officers, and Financial Statements and Exhibits.
What is LAVA Therapeutics N.V.'s jurisdiction of incorporation?
LAVA Therapeutics N.V. is incorporated in The Netherlands.
Has there been a change in control of LAVA Therapeutics N.V.?
Yes, the filing indicates that there has been a change in control of the registrant.
Filing Stats: 1,401 words · 6 min read · ~5 pages · Grade level 11.9 · Accepted 2025-11-13 08:40:07
Key Financial Figures
- $1.04 — any (" Shares ") at a purchase price of $1.04 per Share plus (ii) one contingent valu
Filing Documents
- tm2530957d3_8k.htm (8-K) — 34KB
- tm2530957d3_ex99-1.htm (EX-99.1) — 12KB
- tm2530957d3_ex99-1img001.jpg (GRAPHIC) — 18KB
- 0001104659-25-110913.txt ( ) — 242KB
- lvtx-20251112.xsd (EX-101.SCH) — 3KB
- lvtx-20251112_lab.xml (EX-101.LAB) — 33KB
- lvtx-20251112_pre.xml (EX-101.PRE) — 22KB
- tm2530957d3_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated November 13, 2025. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document Important Additional Information and Where to Find It The description contained in this Current Report on Form 8-K is for informational purposes only and is not a recommendation, an offer to buy or the solicitation of an offer to sell any of the Company's common shares. The Subsequent Offering Period will expire at 11:59 p.m., New York City time, on November 19, 2025. Buyer has filed a Tender Offer Statement on Schedule TO and the Company has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC related to the Offer. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND RELATED DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES (INCLUDING THE TERMS AND CONDITIONS OF THE OFFER). Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov. Investors and security holders may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the "SEC Filings" subsection of the "Financial Information" section of the Company's website at https://ir.lavatherapeutics.com/. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LAVA Therapeutics N.V. Date: November 13, 2025 By: /s/ Fred